How Do They Treat MS? Medications, Therapy & More

Multiple sclerosis treatment works on several fronts at once: stopping acute attacks when they happen, slowing the disease’s long-term progression with disease-modifying therapies, and managing the day-to-day symptoms that affect quality of life. There is no single pill or procedure that covers all three goals, so most people with MS end up on a combination of treatments that evolves over time. The good news is that the treatment landscape has expanded dramatically over the past two decades, and the options now range from self-injected drugs developed in the 1990s to potent monoclonal antibodies and even stem cell transplants.

Treating a Relapse When It Hits

An MS relapse, sometimes called a flare or exacerbation, is a period when new neurological symptoms appear or old ones get noticeably worse because of fresh inflammation in the brain or spinal cord. The standard first-line treatment is a short course of high-dose intravenous corticosteroids, typically methylprednisolone given over three to five days.¹ Corticosteroids do not change the long-term course of the disease, but they shorten the duration and severity of the relapse by tamping down inflammation quickly.

When steroids are not enough, or when someone cannot tolerate them, doctors may turn to therapeutic plasma exchange. This procedure filters the blood to remove the antibodies and inflammatory molecules driving the attack. In one study tracking patients over two years, about 78% of those who received plasma exchange after an inadequate steroid response showed clinical improvement, and their disability scores were lower at both six months and two years compared to matched controls who did not receive the treatment.² Younger patients and those whose MRI scans showed active inflammation tended to benefit the most.

Disease-Modifying Therapies: The Backbone of Long-Term Treatment

The treatments that get the most attention in MS are disease-modifying therapies, or DMTs. These don’t cure MS, but they reduce how often relapses happen and slow the accumulation of disability. The number of approved DMTs has grown from a handful in the mid-1990s to more than 20 today, and they fall into a few broad categories based on how they are taken and how aggressively they suppress disease activity.

Injectable Therapies

The earliest approved DMTs were interferon beta and glatiramer acetate, both given by injection. Interferons work by triggering a cascade of immune-modulating signals. Among other things, they quickly reduce leakage across the blood-brain barrier, which is how immune cells sneak into the brain and cause damage.³ Glatiramer acetate takes a different approach: it is a synthetic molecule that competes with myelin proteins for the attention of immune cells and nudges the immune response toward an anti-inflammatory profile. Glatiramer acetate also stimulates the production of brain-derived neurotrophic factor, a protein involved in nerve cell health.⁴

These injectable drugs are considered moderate-efficacy treatments. They reduce relapse rates by roughly a third compared to placebo, and their safety profiles are well established after decades of use. Their main downside is convenience: injections can be daily, every other day, or a few times a week depending on the formulation, and injection-site reactions are common.

Oral Therapies

The arrival of oral DMTs was a turning point for many people with MS who were tired of needles. Fingolimod, teriflunomide, and dimethyl fumarate were the first to gain regulatory approval, and others have followed.⁵ Each works through a distinct mechanism. Fingolimod traps immune cells in the lymph nodes so fewer of them can travel to the brain. Dimethyl fumarate activates a cellular defense pathway that protects against oxidative stress. Teriflunomide blocks a step in the production of fast-dividing immune cells.⁶ Other oral options now include cladribine, which works by selectively depleting lymphocytes in short treatment pulses, and siponimod, a more selective cousin of fingolimod.

Oral therapies sit across a range of efficacy. Some, like teriflunomide, are comparable to the older injectables. Others, like cladribine, are considered higher-efficacy and are sometimes reserved for more active disease.

Monoclonal Antibodies

The most potent widely used DMTs are monoclonal antibodies given by infusion or injection. A major class targets a protein called CD20 on the surface of B cells, effectively depleting a population of immune cells that plays a central role in MS inflammation. Rituximab, ocrelizumab, ofatumumab, and ublituximab all work this way.⁷ Natalizumab takes a different approach, blocking the molecule immune cells use to cross the blood-brain barrier. Alemtuzumab depletes a broad set of immune cells and essentially resets portions of the immune system.

These drugs are highly effective at preventing relapses and new brain lesions, but their potency comes with trade-offs, particularly around infection risk, which is discussed further below.

Starting Strong Versus Escalating Gradually

One of the biggest debates in MS treatment over the past decade is whether to start with a high-efficacy drug right away or begin with a milder therapy and escalate only if disease activity breaks through. The traditional approach was escalation: try an injectable or oral drug first, and step up to a monoclonal antibody if needed. But growing evidence favors starting strong. A study comparing these strategies in a French Caribbean cohort found that patients who started with early intensive therapy remained free of significant disability progression at much higher rates after eight years: roughly 90% of the early intensive group versus about 64% of the escalation group.⁸ Disability scores stabilized or even improved in the intensive group, while they worsened in the escalation group. Multiple other studies from different populations have pointed in the same direction, and many neurologists now lean toward early intensive treatment, especially in younger patients with active disease.

Managing Spasticity and Walking Difficulties

Even when disease-modifying therapy is working well, many people with MS deal with stiffness, muscle spasms, and walking problems. Spasticity is one of the most common and frustrating symptoms. First-line medications for spasticity include baclofen, tizanidine, and gabapentin.⁹ If those are not enough, diazepam or dantrolene may be added. For people who still get inadequate relief, a cannabis-derived mouth spray (nabiximols) has shown positive results as an add-on treatment. In severe cases where oral drugs fail, baclofen can be delivered directly into the spinal fluid via an implanted pump.

Walking speed and endurance are addressed separately. Fampridine (also sold as dalfampridine) is the only drug specifically approved to improve walking in MS. It works by blocking potassium channels on demyelinated nerve fibers, which helps electrical signals travel more efficiently. Studies show it improves gait speed, walking distance, and balance, and these improvements reverse when the drug is stopped and return when it is restarted.¹⁰ A systematic review confirmed that fampridine’s largest effect is on gait speed, with additional gains in endurance and functional mobility.¹¹ Not everyone responds to it, roughly a third of people who try it see a meaningful benefit, but for responders the effect can be significant.

Fatigue, Pain, and Depression

Fatigue is one of the most disabling symptoms of MS and one of the hardest to treat. Modafinil, a wakefulness-promoting drug, has modest but real effects: a meta-analysis of controlled trials found it reduced fatigue scores compared to placebo and improved physical quality of life, though it did not improve mental health-related quality of life specifically.¹² It does carry a higher rate of side effects, particularly insomnia and stomach upset. Amantadine is another option sometimes used off-label for MS fatigue, though the evidence supporting it is thinner.

Neuropathic pain, the burning, stabbing, or electrical-shock sensations caused by nerve damage, affects a large proportion of people with MS. The standard drug options are anticonvulsants and certain antidepressants, though how well they work varies widely from person to person.¹³ A recent network meta-analysis ranked electrical stimulation, cannabis-based medicine, duloxetine, and levetiracetam as more effective than placebo for neuropathic pain, while some commonly used drugs like lamotrigine did not outperform placebo in the same analysis.¹⁴ For the tingling and numbness known as paresthesia, non-drug approaches including aquatic exercise, yoga, acceptance and commitment therapy, and massage all outperformed control conditions.

Depression is roughly two to three times more common in people with MS than in the general population, and it worsens fatigue, pain, and cognitive problems. Both medication (antidepressants) and psychological therapy (particularly cognitive behavioral therapy) reduce depressive symptoms, with moderate effect sizes in both cases.¹⁵ No single approach is considered the gold standard; a combined strategy using therapy, medication, and exercise together has been recommended because each alone tends to be only partially effective.¹⁶

Physical Rehabilitation and Exercise

Exercise and physical therapy are not optional extras in MS management. A dose-response meta-analysis of balance rehabilitation programs found a meaningful effect on balance outcomes across over a thousand participants, and higher-intensity, task-specific interventions produced better results.¹⁷ Structured balance training programs have also been shown to reduce actual falls and the proportion of people who are fallers, even though participants may not report improved confidence in their balance.¹⁸

Beyond preventing falls, exercise appears to have direct biological effects on the brain. Physical activity boosts blood levels of brain-derived neurotrophic factor (BDNF), a protein that supports nerve cell survival and the growth of new connections. People with relapsing-remitting MS tend to have lower BDNF levels than healthy controls, but exercise can close that gap. A 24-week training program increased BDNF levels in people with MS compared to a non-exercise control group.¹⁹ A meta-analysis of exercise trials confirmed that BDNF levels rise after training programs.²⁰ This matters because BDNF is involved in neuroplasticity, the brain’s ability to rewire itself around damage. While the clinical implications of raising BDNF are still being studied, the finding adds biological plausibility to the consistent observation that regular exercise improves function and quality of life in MS.

Infection Risk and Vaccinations

Because most DMTs work by suppressing or modifying parts of the immune system, infection is the most common category of serious side effect across the board.²¹ The type and severity of infection risk vary by drug. Fingolimod has been associated with the most opportunistic infections among drugs in its class, though newer related drugs do not carry the same track record. Teriflunomide and dimethyl fumarate, once considered relatively low risk, have over time been linked to several infections as more real-world data have accumulated.²²

Reactivation of latent viruses is a specific concern. In one three-year observational study, patients on anti-CD20 therapies and natalizumab experienced reactivations of herpes simplex virus, and a cladribine-treated patient developed shingles from varicella-zoster reactivation. One patient on ocrelizumab had a hepatitis B reactivation. All reactivations were successfully treated.²³ Pre-treatment screening for hepatitis B, tuberculosis, and varicella-zoster immunity is now standard practice before starting most potent DMTs.

Vaccinations present a nuanced picture. Anti-CD20 therapies substantially blunt antibody responses to vaccines, which can make standard blood tests suggest the vaccine did not work. However, the T-cell arm of the immune response remains robust, meaning vaccination is still beneficial even when antibody levels look disappointing on paper.²² The practical takeaway is to get recommended vaccines, ideally before starting a B-cell-depleting therapy if possible, but not to skip them if you are already on one.

Vitamin D and Relapse Risk

Vitamin D is the most studied environmental factor in MS, and the association between low vitamin D levels and worse disease activity is consistent across many studies. Higher blood levels of vitamin D correlate with a lower risk of relapses, less disability, and reduced disease severity.²⁴ One study found that each doubling of blood vitamin D concentration was associated with a 27% decrease in relapse rate.²⁵ Another found that each modest increase in vitamin D was tied to about a 7% drop in relapse risk, with patients whose levels exceeded a certain threshold having significantly fewer relapses than those with the lowest levels.²⁶

The important caveat is that these are observational findings. It is possible that low vitamin D is partly a consequence of MS rather than purely a cause, since people with more disability may spend less time outdoors. Large randomized trials of vitamin D supplementation in MS have not produced the dramatic results the observational data might lead you to expect. Most neurologists still recommend that their MS patients maintain sufficient vitamin D levels, but vitamin D supplementation alone is not considered a substitute for disease-modifying therapy.

Stem Cell Transplant

Autologous hematopoietic stem cell transplantation (AHSCT) is the most intensive treatment available for MS. It involves harvesting a person’s own blood stem cells, wiping out the immune system with chemotherapy, and then reinfusing the stem cells to rebuild a new immune system from scratch. The goal is to eliminate the rogue immune cells attacking the brain and spinal cord.

The results can be striking. A meta-analysis found that about 81% of patients remained relapse-free after AHSCT, and roughly 68% achieved no evidence of disease activity, meaning no relapses, no disability progression, and no new brain lesions.²⁷ A head-to-head comparison with high-efficacy drugs found that AHSCT led to fewer relapses than fingolimod and natalizumab, with relapse rates comparable to ocrelizumab. Patients who received AHSCT were also more likely to experience confirmed disability improvement than those on fingolimod or natalizumab.²⁸

The trade-off is risk. About 23% of AHSCT patients in one analysis experienced febrile neutropenia during the preparation phase, roughly 11% developed serum sickness, and about 9% needed intensive care admission. The majority of serious adverse events after discharge were infections, particularly viral ones. Transplant-related mortality has dropped substantially with experience, falling from about 3.6% before 2005 to around 0.3% more recently.²⁹ AHSCT is generally considered for younger patients with highly active relapsing MS who have not responded adequately to high-efficacy DMTs. It is not currently recommended for progressive MS without active inflammation.

Monitoring Treatment With Blood Biomarkers

Deciding whether a treatment is working used to rely almost entirely on clinical relapses and periodic MRI scans. A newer tool is neurofilament light chain (NfL), a protein released into the blood when nerve fibers are damaged. Patients with lower NfL levels are more likely to achieve a state of no detectable disease activity.³⁰ In early MS, patients with active disease and high NfL levels have substantially higher odds of continued disease activity the following year compared to those with low NfL, and they also lose more brain volume.³¹ NfL is increasingly being used alongside MRI to give a more complete picture of whether the disease is truly quiet or whether a treatment switch might be warranted.

Pregnancy and Breastfeeding

Family planning is a major consideration for the many people diagnosed with MS during their reproductive years. Pregnancy itself has a protective effect on MS: relapse rates tend to drop during pregnancy, especially in the third trimester, but they can rebound in the months after delivery. The key question is what to do about disease-modifying therapy around conception, pregnancy, and breastfeeding.

Observational data support the safety of injectable DMTs, specifically glatiramer acetate and interferon beta, during pregnancy. Some oral DMTs carry fetal risks and need to be stopped well before conception. Monoclonal antibodies like rituximab and natalizumab used before pregnancy do not appear to pose significant fetal risks, but they can cross the placenta from the second trimester onward and may temporarily affect the baby’s blood counts if given too late in pregnancy.³² Exclusive breastfeeding appears to reduce the risk of postpartum relapses, and the injectable therapies and monoclonal antibodies are thought to transfer minimally into breast milk.³³ The overarching recommendation from MS specialists is to discuss family planning early and revisit it regularly, because the timing of stopping and restarting treatment needs to be individualized.³⁴

Pediatric MS

MS diagnosed in children and adolescents accounts for a small percentage of all cases, but it tends to be more inflammatory: kids with MS often have more frequent relapses than adults. Treatment decisions are complicated by the limited number of drugs formally studied in pediatric populations. In practice, many of the same DMTs used in adults are prescribed off-label, and choices are guided by disease severity, the child’s age, and family preferences.³⁵ A meta-analysis of pediatric studies found that high-efficacy therapies like natalizumab and ocrelizumab produced a greater reduction in relapse rate and disability than moderate-efficacy therapies.³⁶ Close monitoring for side effects and disease breakthrough is especially important in younger patients, and research into pediatric-specific formulations and dosing is ongoing.³⁷

What Is Coming Next

The most watched class of drugs in the MS pipeline is Bruton’s tyrosine kinase inhibitors, or BTK inhibitors. These are small molecules that can cross the blood-brain barrier, which most existing DMTs cannot do effectively. BTK inhibitors target an enzyme involved in the function of both B cells and microglia, the resident immune cells of the brain. The hope is that by modulating immune activity inside the brain itself, BTK inhibitors could address the smoldering inflammation thought to drive progressive disability even when relapses are controlled.³⁸ Several BTK inhibitors are in late-stage clinical trials, though results so far have been mixed, and safety signals around liver toxicity have complicated the development of some candidates.

One proposed strategy is to pair early anti-CD20 therapy, which preserves existing myelin and nerve fibers, with a CNS-penetrant BTK inhibitor that could promote repair by calming the microglia that sustain chronic inflammation.³⁹ If this combination approach pans out, it could mark a shift from simply suppressing the immune system to actively encouraging the brain to repair itself, a goal that has been frustratingly out of reach in MS research for decades. Diet and gut microbiome modulation are also areas of growing interest: various dietary patterns may influence the gut bacteria that interact with the immune system, and early research suggests this could become a complementary tool, though it is not yet ready for formal clinical recommendations.⁴⁰